Edition:
United States

Novozymes A/S (NZYMb.CO)

NZYMb.CO on Copenhagen Stock Exchange

272.90DKK
4:41am EDT
Change (% chg)

kr.1.10 (+0.40%)
Prev Close
kr.271.80
Open
kr.272.50
Day's High
kr.273.60
Day's Low
kr.272.20
Volume
83,801
Avg. Vol
597,353
52-wk High
kr.334.60
52-wk Low
kr.220.70

NZYMb.CO

Chart for NZYMb.CO

About

Novozymes A/S is a Denmark-based biotechnology company engaged in the production and sale of industrial enzymes, microorganisms and biopharmaceutical ingredients. The Company operates in four geographical regions: Europe, Middle East & Africa (including Denmark), North America, Asia Pacific and Latin America. It develops and... (more)

Overall

Beta: 0.93
Market Cap(Mil.): kr.69,650.49
Shares Outstanding(Mil.): 256.26
Dividend: 4.00
Yield (%): 1.47

Financials

  NZYMb.CO Industry Sector
P/E (TTM): 27.00 22.61 124.31
EPS (TTM): 10.07 -- --
ROI: 20.63 15.66 10.17
ROE: 26.17 23.83 13.18

BRIEF-Dong Energy to build biogas plant for Novo Nordisk, Novozymes residues

* Says will in cooperation with Bigadan build a large-scale biogas plant

Mar 23 2017

BRIEF-Coor Service Management Holding signs agreement with Novozymes in Denmark

* Delivery to Novozymes starts May 1 Source text: http://bit.ly/2mviZql

Mar 23 2017

BRIEF-Novozymes President and CEO buys 27,700 shares at DKK 6,997,574

* President and CEO Peder Holk Nielsen buys 27,700 shares in Novozymes at 6,997,574 Danish crowns ($1 million) Source text for Eikon:

Jan 26 2017

BRIEF-Novozymes initiates stock buyback program

* Will buy back B shares worth up to 2 billion Danish crowns ($288.9 million) in total during remainder of 2017, corresponding to around 8.1 million B shares at current share price

Jan 24 2017

BRIEF-Novozymes EVP Anders Lund sells shares at about DKK 3.6 million

* Executive Vice President Anders Lund has sold 14,477 shares in Novozymes at about 3.6 million Danish crowns ($519,691)

Jan 23 2017

Novozymes cuts jobs, says U.S. policy, Monsanto deal pose risks

COPENHAGEN Enzymes maker Novozymes will cut 198 jobs and invest more in emerging markets, it said on Wednesday, adding it could time take to recapture past growth rates amid uncertainty over U.S. renewable energy policy and the takeover of a key partner.

Jan 18 2017

UPDATE 1-Novozymes cuts jobs, says U.S. policy, Monsanto deal pose risks

* Q4 earnings beat expectations, to buy back shares (Adds CEO comments)

Jan 18 2017

European shares boosted by company updates, though Pearson plummets

LONDON, Jan 18 European shares edged higher on Wednesday in early deals, helped by a slew of well-received company results from ASML, Novozymes and Burberry, though shares in Pearson slumped after its update.

Jan 18 2017

Novozymes cuts 198 jobs, to invest more in emerging markets

COPENHAGEN, Jan 18 Danish enzymes maker Novozymes said on Wednesday it would cut 198 jobs and allocate resources to high-growth opportunities in emerging markets, indicating it could take time to return to previous growth rates.

Jan 18 2017

BRIEF-Novozymes Q4 EBIT DKK 1.06 billion, beats expectations

* Q4 sales 3.71 billion Danish crowns (Reuters poll 3.60 billion crowns)

Jan 18 2017

More From Around the Web

Earnings vs. Estimates